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Summary 
 
This guideline provides recommendations for the clinical care of patients with 
astrocytic and oligodendroglial gliomas of adulthood. It is based on the 2016 WHO 
classification of tumors of the nervous system and on scientific developments since 
the 2014 version of the guideline. The recommendations focus on pathological and 
radiological diagnostics as well as the major treatment modalities of surgery, 
radiotherapy and pharmacotherapy. The results from contemporary practice-
changing clinical trials have been integrated. The guideline aims to provide guidance 
for diagnostic and management decisions while limiting unnecessary treatment and 
cost. It is a source of knowledge for professionals involved in the management of 
glioma patients, for patients and caregivers, and for health care providers in Europe. 
Implementing this guideline requires multidisciplinary and multiprofessional structures 
of care and defined processes of diagnosis and treatment. 
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Search strategy and selection criteria 
This guideline was prepared by a task force nominated by the Executive Board of the 
European Association for Neuro-Oncology (EANO) in cooperation with the Brain 
Tumor Group of the European Organization for Research and Treatment of Cancer 
(EORTC) in 2016. The task force represents the disciplines involved in the diagnosis 
and care of glioma patients and reflects the multinational character of EANO. 
References were retrieved onPubMed with the search terms “glioma”, “anaplastic”, 
“astrocytoma”, “oligodendroglioma”, “glioblastoma”, “trial”, “clinical”, “radiotherapy” 
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and “chemotherapy” from January 2001 to July 2016. Publications were identified 
through searches of the authors` own files, too. Only papers in English were 
reviewed. Data available only in Abstract form were only exceptionally included. The 
definitive reference list was generated based on relevance to the broad scope of this 
guideline. 
 
Introduction 
This guideline follows the revision of the fourth edition of the World Health 
Organization (WHO) Classification of Tumors of the Central Nervous System1 and 
builds on previous guidelines.2,3 It addresses astrocytic and oligodendroglial gliomas 
of WHO grades II-IV of adulthood and their variants and covers prevention, early 
diagnosis and screening, therapy, and follow-up. It does not address differential 
diagnosis, adverse effects of treatment, or supportive or palliative care. 
 
Diagnostics 
 
Early diagnosis and screening 
The annual incidence of gliomas is in the range of 6/100,000. Serum markers for 
early detection have not been identified. Instead, brain magnetic resonance imaging 
(MRI) has the highest sensitivity to detect small tumors. Gliomas can evolve rapidly 
over several weeks or months, emphasizing the challenges for population-based 
prevention or early intervention. Screening is therefore limited to persons at genetic 
risk, for example, patients with neurofibromatosis type I, or Turcot and Li Fraumeni 
syndromes. No repeat scanning is indicated in such individuals unless clinically 
justified. A particular challenge is counseling and screening of relatives of patients 
whose tumors carry germline mutations associated with gliomagenesis.4 Prevention 
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strategies are not available. 
 
History and clinical examination 
The evolution of neurological symptoms and signs allows to estimate the growth 
dynamics of gliomas and may reveal familial risk or exogenous risk factors including 
exposure to irradiation or other conditions associated with brain tumors. Relatives 
may be required to obtain a reliable history. Characteristic modes of presentation are 
new onset epilepsy, focal deficits including neurocognitive impairment, and indicators 
of intracranial mass effect. The physical examination focuses on the detection of 
systemic cancer and contraindications for neurosurgical procedures. Neurocognitive 
assessment beyond documenting the Karnofsky performance score (KPS) or the 
WHO performance status and performing a Mini Mental State Examination (MMSE) 
or a Montreal Cognitive Assessment has become increasingly common.5,6 
 
Ancillary studies 
MRI before and after application of gadolinium is the standard method to detect a 
glioma.7 In addition, cranial computed tomography (CT) demonstrates calcifications, 
intra-arterial angiography may aid the surgical strategy, and amino acid positron 
emission tomography (PET) helps define metabolic hotspots for biopsy.8 
Standardized MRI sequences are also recommended to assess the efficacy of 
therapeutic interventions.9 Cerebrospinal fluid studies play no major role in the 
diagnostic work-up of gliomas and lumbar punctures carry the risk of neurological 
deterioration in patients with large space-occupying tumors. Electroencephalography 
helps for monitoring tumor-associated epilepsy and in determining causes of altered 
consciousness. 
 
7 
 
Preoperative management 
Management should follow written local standard operating procedures and 
multidisciplinary discussion preferentially including dedicated neuroradiologists and 
neuropathologists as well as neurosurgeons, radiation oncologists and 
neurooncologists in a brain tumor board. Prior to surgery, unless there are 
contraindications or the suspicion of primary cerebral lymphoma or inflammatory 
lesions, corticosteroids may be administered to decrease tumor-associated edema. 
Additional pharmacological measures such as osmotic agents are rarely necessary. 
Glioma patients who have suffered epileptic seizures should receive anticonvulsant 
drugs preoperatively. Primary prophylaxis is not indicated in patients without 
seizures.10 
 
Biopsy or resection 
Treatment decisions in glioma patients are based on a tissue diagnosis and the 
assessment of selected molecular markers. Surgery is thus commonly performed 
with diagnostic and therapeutic objectives. The surgical management of glioma 
patients should take place in high-volume specialist centers. A decision for palliative 
care without histological diagnosis should be avoided unless the risk of the biopsy 
procedure is considered too high or if the prognosis is likely to be very unfavourable, 
e.g., in old patients with large tumors and rapid clinical decline. Stereotactic serial 
biopsies along the trajectory under local anesthesia are associated with low morbidity 
and a firm diagnosis aids counselling patients and relatives also when tumor-specific 
therapy is not recommended. Serial sampling allows to avoid undergrading, the 
procedure requires close cooperation between neuropathologist, neuroradiologist 
and neurosurgeon. 
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Histological classification and molecular diagnostics 
Intraoperative assessment of cytological specimens or frozen sections before the 
surgical procedure is terminated assure that sufficient tissue is obtained to establish 
a diagnosis. Tumor tissue is formalin-fixed and embedded in paraffin for conventional 
histological staining, including routine hematoxylin-eosin staining and additional 
immunohistochemical and molecular analyses. If possible, a part of the tissue should 
be cryopreserved for future scientific molecular marker studies. The diagnostic 
process follows the WHO classification and consists of histological tumor typing as 
well as tumor grading using the four-tiered WHO grading scheme from WHO grade I 
to IV, designed to provide clinicians with information on the tumor's biological 
behavior and consequently the patient's prognosis and outcome (Fig. 1). The 2016 
WHO classification recognizes the major diagnostic role of isocitrate dehydrogenase 
(IDH) 1 codon 132 or IDH2 codon 172 missense mutations ("IDH mutation") and 
defines diffuse and anaplastic astrocytic and oligodendroglial gliomas essentially as 
IDH-mutant tumors.1 Oligodendroglial tumors additionally carry 1p/19q co-deletions. 
IDH-wildtype diffuse and anaplastic astrocytomas are considered provisional entities. 
“Not otherwise specified” (NOS) categories have been introduced for those gliomas 
that cannot be tested for the diagnostically relevant markers or for which testing 
remains inconclusive. Management recommendations for these NOS categories are 
included in Table 1, but evidence is low. Oligoastrocytomas and gliomatosis cerebri 
both lack distinctive genetic and epigenetic profiles11,12 and are thus no longer 
considered as distinct glioma entities.1 Diffuse midline glioma, H3-K27M-mutant, has 
been introduced as a novel entity characterized by midline tumor location and 
presence of lysine to methionine mutation at codon 27 of histones 3.3 or 3.1.1  
Altogether, four molecular markers are central to diagnosing and treating gliomas: 
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IDH mutation, 1p/19q co-deletion, H3-K27M mutation and O6-methylguanine DNA 
methyltransferase (MGMT) promoter methylation. IDH mutation, 1p/19q co-deletion 
and H3-K27M mutation are assigned a role in the revised WHO classification (Table 
1) whereas MGMT promoter methylation status guides treatment decisions regarding 
the use of chemotherapy.13 Immunohistochemical detection of loss of nuclear ATRX 
expression is helpful to substantiate the diagnoses of IDH-mutant diffuse and 
anaplastic astrocytomas, and if retained should prompt testing for 1p/19q co-deletion 
in IDH-mutant gliomas, however, ATRX immunohistochemistry shall not substitute for 
1p/19q codeletion testing. High-throughput assays will probably soon be introduced 
instead of single marker assessments. 
 
 
Therapy - General recommendations 
 
Prognostic factors 
Younger age and better performance status are important positive, therapy-
independent prognostic factors across glioma entities. Extent of resection is an 
important therapy-dependent prognostic factor. Prognostically favorable molecular 
markers such as IDH mutation and 1p/19q co-deletion are now at the core of the 
WHO classification and define more homogeneous diagnostic and prognostic 
entities.1,13 
 
Surgical therapy 
Beyond establishing a histological diagnosis, the goal of surgery is to remove as 
much of the tumor as is safely possible with the goal of improving neurological 
function. Microsurgical techniques are standard. Several tools including surgical 
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navigation systems housing functional MRI datasets, intraoperative MRI, ultrasound, 
intraoperative functional monitoring and the fluorescent dye, 5-aminolevulinic acid 
(ALA), to visualize tumor tissue14 help increase the extent of resection while keeping 
the risk of new neurological deficits low. The use of evoked potentials, 
electromyography or mapping in awake patients under local anesthesia to monitor 
and preserve language and cognition should support resections in eloquent areas. 
Preventing new permanent neurological deficits is more important than extent of 
resection because gliomas are not cured by surgery: this is precluded by tumor cell 
infiltration far beyond the lesion as delineated by neuroimaging and network-like 
growth, hallmarks of diffuse gliomas.15 Postoperative deficits due to emerging 
complications are a negative prognostic factor. Furthermore, quality of life is a high 
priority to patients and carers. The result of surgery is assessed by early MRI – or CT 
if MRI is not possible - without and with contrast and diffusion imaging within 24-72 h 
of surgery.16  
 
Radiotherapy (RT) 
The goal of RT for patients with gliomas is to improve local control at a reasonable 
risk benefit ratio. RT helps to preserve function and increases survival. Indications 
for, timing, dosing and scheduling of RT are determined by diagnosis and prognostic 
factors, including age, KPS and extent of resection.17 Focal RT is administered at 50-
60 Gy in 1.8-2 Gy fractions, depending on prognosis defined by tumor type and 
grade. Hypofractionated RT with higher fraction sizes and lower total dose e.g., to 15 
x 2.67 Gy, is appropriate in older patients and those with poor prognostic factors, and 
considered biologically equivalent to 30 x 2 Gy. The area of residual enhancement on 
T1 imaging plus the surgical bed is defined as the gross tumor volume. A margin, 
typically 1.0-1.5 to 2.5 cm including the hyperintensity on T2 / FLAIR imaging is 
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added to define the clinical target volume which is then modified in areas where 
microscopic spread is unlikely, or to reduce the dose to critical structures. Finally 
another margin, usually 0.3 to 0.5 cm, is added to allow for error setup and 
movement during treatment, generating the planning target volume.18 PET is studied 
for improving target delineation in clinical trials.8  
The organs at higher risk of radiotherapy-associated toxicity including optic nerves, 
optic chiasm, retinae, lenses, brainstem, pituitary, cochleas and hippocampus should 
be delineated. Modern techniques of focused RT, e.g. stereotactic, intensity-
modulated or image-guided RT may improve the targeted delivery of RT to better 
protect surrounding tissue. In children especially, but also in adults with deeply 
localized tumors, interstitial brachytherapy and proton/heavy ions radiotherapy may 
be alternatives. Randomized data comparing such novel approaches with standard 
techniques are not available. 
 
Pharmacotherapy 
Cytotoxic chemotherapy is standard of care for most glioma patients (Table 2). It 
requires regular hematology, hepatic and renal laboratory and exclusion of major 
lung or heart disease and infection. Blood counts need to be monitored during 
therapy. Temozolomide (TMZ), an oral DNA alkylating agent with good blood brain 
barrier penetration, is widely used in glioma treatment and has a favourable safety 
profile, with myelosuppression, notably thrombocytopenia as its main and dose-
limiting toxicity. Hepatic function should also be assessed regularly. In contrast to 
TMZ, nitrosoureas such as lomustine (CCNU), carmustine (BCNU), nimustine 
(ACNU) or fotemustine cause prolonged leukopenia and thrombocytopenia. This may 
necessitate delays of further treatment at reduced dose or even discontinuation and 
consideration of alternative treatments. Pulmonary fibrosis is probably most often 
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seen with carmustine. Nitrosoureas have become a second choice after TMZ for 
glioma treatment in most European countries, although data from larger comparative 
trials are missing and retrospective or subgroup analyses suggest a higher efficacy of 
procarbazine, lomustine (CCNU) and vincristine (PCV) over TMZ in good prognosis 
patients with anaplastic glioma.19,20 Locally delivered carmustine wafers (Gliadel®) 
implanted into the surgical cavity have provided a moderate survival advantage to 
patients with newly diagnosed grade WHO III or IV gliomas, or recurrent 
glioblastoma,21 but are now a rarely considered option, and mostly in patients without 
systemic treatment options. Their application requires careful patient selection and a 
gross total resection. Among various candidate anti-angiogenic agents explored in 
clinical trials in glioma patients, only bevacizumab, an antibody to vascular 
endothelial growth factor, is approved for recurrent glioblastoma in the USA, Canada, 
Switzerland and several other countries outside the European Union. Glioma patients 
undergoing systemic therapy should carry a documentation of treatment including 
laboratory results and information on complications and contraindications. Clinical 
centers managing glioma patients should generate standard operating procedures 
and instructions for handling side effects and complications from treatment. 
 
Other therapeutic approaches 
Other approaches to glioma therapy including various targeted and immunological 
therapies, notably immune checkpoint inhibitors, are of unknown activity and should 
be explored within clinical trials. 
 
Monitoring and follow-up 
In addition to clinical examination, MRI is the standard diagnostic measure for the 
evaluation of disease status or treatment response. Three months intervals are 
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common practice initially for most patients, but longer intervals are appropriate in 
case of durable disease control and less aggressive tumors. Vice versa, in case of 
suspected disease progression short term control MRI may be reasonable to confirm 
progression. Pseudoprogression and pseudoresponse are most likely to occur during 
the first three months of treatment. Particular attention is needed when interpreting 
scans during this period. The Response Assessment in Neuro-Oncology (RANO) 
working group has recommended that assessment of non-contrast-enhancing tumor 
components should be an additional key component of response criteria.9 
 
 
Specific recommendations 
 
Figures 2 and 3 and Table 1 provide an overview of therapeutic approaches. Table 3 
provides the key recommendations. 
 
Diffuse astrocytoma, IDH-mutant – WHO grade II 
These are the most common WHO grade II astrocytomas. Gemistocytic 
astrocytomas are a subtype of IDH-mutant diffuse astrocytoma.1 Maximum surgical 
resection as feasible is increasingly considered the best initial therapeutic measure. 
Watch-and-wait strategies without establishment of a diagnosis are less commonly 
pursued. Asymptomatic younger patients with seizures only can be managed by 
observation alone after gross total resection. Involved field RT (50 Gy) should be 
considered for patients with incomplete resection and patients older than 40 years. It 
prolongs progression-free survival (PFS), but not overall survival (OS).22 
Chemotherapy alone as initial treatment should be considered investigational, but 
may be an option in patients with extensive tumors although PFS is shorter with TMZ 
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than with RT.23 The RTOG 9802 trial reported a major prolongation of survival by 
adding PCV polychemotherapy to RT (54 Gy) compared with RT alone from 7.8 to 
13.3 years in patients with high-risk WHO grade II gliomas who were 18 to 39 years 
of age and had undergone a subtotal resection or biopsy, or who were 40 years of 
age or older. RT followed by PCV constitutes a new standard of care, given the lack 
of other up-coming clinical trial results likely to challenge these data. Benefit was 
reported across histological subgroups and, although data are limited, there was no 
overt link between benefit from PCV and a particular molecular marker profile, 
potentially due to limited power.24 Treatment at progression depends on first-line 
therapy and may involve second surgery, radiotherapy in previously un-irradiated 
patients or alkylating agent chemotherapy. TMZ is often preferred over PCV 
polychemotherapy because of its favorable safety profile and ease of administration. 
IDH-wildtype diffuse astrocytomas can take a rather aggressive course, resembling 
glioblastoma, in particular in the elderly, but there are also less aggressive variants.25 
 
Anaplastic astrocytoma, IDH-mutant – WHO grade III 
These are the most common WHO grade III astrocytomas. Standard of care includes 
maximal surgical removal or biopsy followed by RT at 60 Gy in 1.8–2 Gy fractions 
(Table 1), largely based on trials where these tumors were pooled with 
glioblastomas. The NOA-04 trial showed that PCV or TMZ alone were as active as 
RT alone for PFS and OS.20,26 The EORTC 26053 trial (CATNON) explored whether 
the addition to RT of concomitant or maintenance TMZ or both improved outcome 
over RT alone in patients with newly diagnosed 1p/19q-non-codeleted anaplastic 
gliomas in a 2 by 2 design. A first interim analysis showed that 12 cycles of 
maintenance TMZ prolonged OS which should now be considered standard of care 
whereas no statement on the value of concomitant TMZ can be made at present.27 
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Molecular marker studies in the CATNON trial are pending. A retrospective study of 
pooled datasets indicated that specifically patients with IDH-wildtype tumors with 
MGMT promoter methylation benefit from alkylating agent chemotherapy.28 
First-line therapy informs on the choices of treatment in the recurrent setting. An 
indication for second surgery should be explored. For patients relapsing after 
radiotherapy re-irradiation is an option with a minimum in the range of 12 months 
interval since the end of the first RT course. However, size and patterns of 
recurrence limit the options of re-RT, and the overall efficacy remains uncertain; 
randomized data are lacking. Alkylating agent chemotherapy should be considered 
for chemo-naive patients who progress after RT, TMZ and nitrosoureas probably 
being equally effective.29,30 Bevacizumab is used after failure of RT and 
chemotherapy, with PFS rates at 6 months of 20-60%.31,32 Controlled data are 
lacking, including for combining bevacizumab with chemotherapy. 
 
Glioblastoma, IDH-wildtype - WHO grade IV 
The majority of histological glioblastomas are IDH-wildtype, including the 
morphological variants of giant cell glioblastoma, gliosarcoma and epitheloid 
glioblastoma. There are to date no specific treatment recommendations for 
glioblastoma variants. About 50% of the rare epitheloid glioblastomas carry a 
druggable BRAF-V600E mutation, but the promising efficacy of BRAF inhibitors 
remains to be evaluated systematically. The following applies to IDH-wildtype 
glioblastoma; IDH-mutant glioblastomas are increasingly treated like IDH-mutant 
anaplastic astrocytoma. 
Surgery for glioblastoma should be gross total resection whenever feasible. A small 
randomized trial in patients WHO grade III and IV tumors aged > 65 reported 
improved survival with resection versus biopsy,33 but remains debated for limited 
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sample size and KPS imbalances between groups. While some studies reported 
gradually improved outcome with increasing extent of resection, only gross total 
resection may be associated with improved outcome.34,35 
RT has been standard of care for glioblastoma for decades, roughly doubling 
survival.17,36 Standard dose is 60 Gy in 1.8-2 Gy fractions; 50 Gy in 1.8 Gy fractions 
improved survival relative to best supportive care in patients 70 years or older with 
good KPS.37 Patients with unfavorable prognostic factors defined by age or KPS are 
treated with hypofractionated RT, e.g., 40 Gy in 15 fractions.38 In the elderly, this is 
the standard of care for patients with tumors without MGMT promoter 
methylation.39,40 Further hypofractionation to 5 x 5 Gy may be feasible without 
compromising survival,41 but is unlikely to be well tolerated in terms of neurocognitive 
side effects which will assume more relevance once other treatment options allow 
long-term survival in elderly glioblastoma patients, too. Neither accelerated hyper- or 
hypofractionated regimens nor brachytherapy, radiosurgery or a stereotactic RT 
boost are superior to standard regimens for survival. 
Concomitant and maintenance TMZ chemotherapy plus RT (TMZ/RT→TMZ) is the 
standard of care for newly diagnosed adult patients in good general and neurological 
condition and aged up to 70 years.42-44 The benefit from TMZ is most prominent in 
patients with MGMT promoter-methylated glioblastoma.45 Recent trials in MGMT 
promoter unmethylated patients showing no detriment from omitting TMZ have raised 
doubts whether TMZ should be used in every patient despite lack of MGMT promoter 
methylation.46-48 There is no benefit from increasing the dose of TMZ in the newly 
diagnosed setting49 and probably also not from extending the duration of 
chemotherapy beyond 6 cycles.50,51 
The NOA-08 and Nordic trials39,40 made MGMT promoter methylation testing  
standard practice in many European countries in the elderly: patients with tumors 
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lacking MGMT promoter methylation should be treated with hypofractionated RT 
alone. This is also the treatment of choice for elderly patients when the MGMT status 
is unknown. Elderly patients with tumors with MGMT promoter methylation should 
receive TMZ alone (5/28 until progression or for 12 months) or TMZ/RT→TMZ. In the 
NCIC CE.6/EORTC 26062 trial enrolling patients ≥ 65 years with newly diagnosed 
glioblastoma, the addition of concomitant and maintenance TMZ to 40 Gy/15 
fractions radiotherapy significantly improved survival. MGMT promoter methylation 
was not prognostic, but highly predictive for benefit from TMZ. Interpretation of the 
benefit from TMZ in patients with MGMT-unmethylated tumors remains controversial. 
There was overall no indication that the benefit from TMZ was reduced with 
increasing age.52 In the absence of comparative data between TMZ alone and 
chemoradiation, elderly patients with MGMT promoter methylation considered eligible 
for combined modality treatment should be offered TMZ/RT→TMZ. Supportive and 
palliative care are appropriate for patients with large or multifocal lesions with low 
KPS, notably if they are unable to consent for further therapy after biopsy. 
Local BCNU wafer chemotherapy added to RT conferred a survival benefit of 13.9 
over 11.6 months with RT alone for the intention-to-treat population of high-grade 
gliomas, but the difference was no longer significant when only glioblastoma patients 
were considered21,44,53 unless extent of resection was included in the analysis where 
the effect was again significant in glioblastoma patients with larger than 90% 
resection.54 
Two randomized trials conducted in the adult glioblastoma patient population have 
demonstrated a gain in PFS of 3-4 months, but not OS, when bevacizumab was 
added to TMZ/RT→TMZ.55,56 The clinical significance of the PFS gain has been 
disputed because the reliability of assessing progression by neuroimaging has been 
questioned and because the RTOG 0825 report raised concerns of early cognitive 
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decline in bevacizumab-treated patients. Bevacizumab was thus not approved for 
newly diagnosed glioblastoma. It may, however, be useful in individual patients with 
large tumors highly symptomatic and resistant to steroids who may otherwise not 
tolerate RT. 
Tumor-treating fields (TTFields) represent a novel treatment modality designed to 
deliver alternating electrical fields to the brain. In an open-label randomized phase III 
trial improved PFS and OS were demonstrated when TTFields were added to 
standard maintenance TMZ in newly diagnosed glioblastoma patients.57 The trial was 
terminated early when the first cohort of 315 randomized patients was analysed and 
a survival benefit was reported (hazard ratio 0.74 (95% CI, 0.56-0.98); log-rank 
p=0.03). Questions regarding mode of action, interpretation of data and impact on 
quality of life have been raised,58 and the place and cost-effectiveness of TTFields in 
the standard of care for newly diagnosed glioblastoma remain to be defined.59 
Standards of care for patients with recurrent glioblastoma are not well defined. 
Clinical decision-making is influenced by prior treatment, age, KPS, and patterns of 
progression. Second surgery is appropriate for 20-30% of patients and is considered 
for symptomatic, but circumscribed lesions and when the interval since the preceding 
surgery exceeds 6 months. Surgery may also be considered earlier in symptomatic 
patients after suboptimal initial surgery. An impact on survival may be limited to 
patients who are candidates for gross total resection of enhancing tumor.60 The 
efficacy of re-irradiation and the value of amino acid PET for target delineation 
remain debated. Fractionation depends on tumor size. Doses of conventional or near 
conventional fractionation using 3-3.5 Gy /fraction to a total dose of 30-35 Gy have 
been tested and several studies using a dose per fraction of 5-6 Gy using 
stereotactic hypofractionated radiotherapy to a total dose of 30-36 Gy or even 
radiosurgery with a single dose of 15-20 Gy have been performed with acceptable 
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toxicity.61 Yet, no relevant monotherapy efficacy was demonstrated in a larger 
randomized trial at 18 x 2 Gy.62 
The main systemic treatment options at progression after TMZ/RT→TMZ in Europe 
are nitrosoureas, TMZ rechallenge, and bevacizumab. CCNU is increasingly 
considered standard of care, based on its activity as the control arm of several 
randomized trials,46,63 with PFS rates at 6 months of 20%. Similar results have been 
reported with alternative dosing regimens of TMZ,64 but activity is probably limited to 
patients with tumors with MGMT promoter methylation.65,66 The BR12 trial showed no 
benefit from dose-intensified TMZ over standard-dose TMZ in TMZ-naïve malignant 
glioma patients,29 but does not inform on the value of TMZ re-challenge for patients 
pre-treated with TMZ. There is thus, however, no reason to administer dose-
intensified TMZ to TMZ-naïve patients. Whether dose-intensified regimens are 
superior to standard-dosed TMZ in recurrent glioblastoma after a TMZ-free interval, 
remains undetermined. 
Bevacizumab is approved for recurrent glioblastoma in various countries throughout 
the world, but not in the European Union, based on response rates in the range of 
30% and PFS and OS times comparing favourably with historical controls in two 
uncontrolled phase II trials.67,68 Its value in clinical practice is widely accepted 
because of transient symptom control and the option for steroid sparing in a subset of 
patients. An effect on OS has not been demonstrated. The superiority of combining 
bevacizumab with CCNU over either agent alone for OS at 9 months65 was not 
confirmed in the EORTC trial 26101.69 No other active combination partner for 
bevacizumab has been identified. TTF were not superior to best physician`s choice in 
a randomized phase III trial.70 
 
Diffuse midline glioma, H3-K27M-mutant 
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This new tumor entity has been assigned the WHO grade IV. It includes the majority 
of brainstem, thalamic and spinal gliomas in children and adults. Surgical options are 
limited and treatment beyond RT is not established. The prognosis is poor. 
Traditionally, treatment has followed the standards for histologically similar gliomas in 
other locations. 
 
Oligodendroglioma, IDH-mutant and 1p/19q-codeleted - WHO grade II 
The new WHO classification defines this tumor as IDH-mutant and 1p/19q-
codeleted.1 In rare instances with lacking or inclusive data on IDH and 1p/19q co-
deletion, tumors are classified as oligodendroglioma, NOS. The diagnosis of 
oligoastrocytoma is discouraged in the new WHO classification. Only exceptional 
cases that cannot be conclusively tested for IDH mutation and 1p/19q co-deletion 
and show a mixed oligoastrocytic histology may still be classified as 
oligoastrocytoma, NOS.1 Surgery is the primary treatment of IDH-mutant and 1p/19q-
codeleted oligodendroglioma. The standard of care is RT followed by PCV if further 
treatment beyond surgery is considered necessary.24 
 
Anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted - WHO grade III 
The new WHO classification defines this tumor as IDH-mutant and 1p/19q-codeleted, 
NOS is only assigned if conclusive molecular information is lacking. The diagnosis of 
anaplastic oligoastrocytoma is discouraged and no longer applicable when tumors 
are successfully tested for IDH mutation and 1p/19q co-deletion. Extent of resection 
is a prognostic factor.26,71 Two large randomized clinical trials – EORTC 26951 and 
RTOG 9402 - showed that the addition of PCV chemotherapy, either prior to or after 
RT, in the first-line treatment prolonged OS by several years in the subset of patients 
with 1p/19q-codeleted oligodendroglial tumors.72,73 Although these results stem from 
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analyses of small patient cohorts, both studies show similar results, validating each 
other and defining the current standard of care. Important questions remain: whether 
long-term survivors treated with RT plus PCV experience preserved cognitive 
function and quality of life74 and whether the same improvement in OS could be 
achieved with TMZ/RT→TMZ. Long-term results from the NOA-04 show that 
chemotherapy alone is not superior to RT alone in either IDH-mutant and 1p/19q-
codeleted anaplastic oligodendroglioma or IDH-mutant anaplastic astrocytoma, 
indicating that alkylating agent chemotherapy alone is unlikely to achieve the same 
outcome as RT combined with PCV. Whether TMZ/RT →TMZ is similarly effective as 
RT followed by PCV is explored in the modified CODEL trial (NCT00887146). 
Treatment at progression is influenced by type of and response to first-line treatment. 
If neither RT nor alkylating agents are options because they failed or because of 
intolerance, bevacizumab has been used,75,76 but is of unknown efficacy as 
controlled studies are lacking. There is no evidence to combine bevacizumab with 
cytotoxic agents in this setting. 
 
Other astrocytic tumors 
Pilocytic astrocytoma and its variant, pilomyxoid astrocytoma, are rare tumors in 
adults and commonly cured by surgery alone. Radiotherapy is only indicated at 
progression when surgical options no longer exist. Pilocytic astrocytoma of the optic 
nerve may be associated with neurofibromatosis type I and cannot be resected 
unless useful visual function has already been lost. These lesions often do not 
require treatment. 
Subependymal giant cell astrocytomas are WHO grade I lesions associated with 
tuberous sclerosis and may respond to mTOR inhibition if treatment beyond surgery 
is required.77 
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Pleomorphic xanthoastrocytoma (WHO grade II) occurs predominantly in children 
and young adults and has a high rate (approximately 70%) of BRAF-V600E mutation. 
It should be resected and patients may be observed after gross total resection. 
Anaplastic pleomorphic xanthoastrocytoma (WHO grade III) should probably be 
managed with postoperative RT and not with a watch-and-wait strategy. In recurrent 
anaplastic pleomorphic astrocytoma, BRAF inhibitors such as vemurafenib appear to 
have limited activity.78 
 
Coordination of care and outlook 
Diagnosis and management plans for glioma patients should follow multidisciplinary 
tumor board recommendations throughout the disease course. Boards are an forum 
to discuss which measures can take place locally, which are better done at a 
specialized center, which are appropriate for in-patient versus out-patient settings, 
and which neurorehabilitation measures are useful. Local and national guidelines as 
well as upcoming EANO guidelines provide further guidance. Guidelines reflect 
knowledge and consensus at a given timepoint. Table 3 summarizes the key 
recommendations of the EANO task force in 2016. The EANO website 
(www.eano.eu) will inform of future updates on this guideline. 
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Table 1 – Key treatment recommendations for patients with diffuse astrocytic and oligodendroglial tumors according to the 
new WHO classification 
 
 Tumor type First-line treatment1 Salvage therapies2,3 Comments / References 
     
 Diffuse astrocytic and 
oligodendroglial tumors 
   
     
 Diffuse astrocytoma, IDH-mutant Wait-and-see or RT→PCV (or 
TMZ/RT→TMZ) 
Nitrosourea (or TMZ 
rechallenge or bevacizumab4)  
RTOG 980224 and per 
extrapolation from WHO 
grade III tumors27  
  Gemistocytic astrocytoma, 
             IDH-mutant  
Wait-and-see or RT→PCV (or 
TMZ/RT→TMZ) 
Nitrosourea (or TMZ 
rechallenge or bevacizumab4) 
 
 Diffuse astrocytoma, IDH-wildtype Wait-and-see (?), RT, 
RT→PCV or TMZ/RT→TMZ, 
(by MGMT status ?) 
TMZ, or Nitrosourea (or TMZ 
rechallenge) or bevacizumab4 
Per extrapolation from IDH-
wildtype glioblastoma42 
 Diffuse astrocytoma, NOS see above, per extrapolation Nitrosourea (or TMZ 
rechallenge or bevacizumab4) 
 
     
 Anaplastic astrocytoma, IDH-mutant (TMZ)/RT→TMZ Nitrosourea or TMZ 
rechallenge or bevacizumab4 
27 
 Anaplastic astrocytoma, IDH-wildtype RT or TMZ/RT→TMZ, by 
MGMT status (?) 
TMZ, or Nitrosourea (or TMZ 
rechallenge) or bevacizumab4 
Per extrapolation from IDH-
wildtype glioblastoma 28,42 
 Anaplastic astrocytoma, NOS see above, per extrapolation Nitrosourea or TMZ 
rechallenge or bevacizumab4 
 
     
 Glioblastoma, IDH-wildtype  
 Giant cell glioblastoma  
 Gliosarcoma  
 Epithelioid glioblastoma 
TMZ/RT→TMZ, > 65-70 
years RT (MGMT 
unmethylated), or 
TMZ/RT→TMZ or TMZ 
(MGMT methylated) 
Nitrosourea or TMZ 
rechallenge or bevacizumab4, 
RT for RT-naïve patients 
39,40,42,52  
 
 Glioblastoma, IDH-mutant (TMZ)/RT→TMZ Nitrosourea or TMZ Per extrapolation from IDH-
42 
 
rechallenge or bevacizumab4 mutant anaplastic 
astrocytoma27 
 Glioblastoma, NOS TMZ/RT→TMZ, > 65-70 
years RT (MGMT 
unmethylated), or TMZ or 
TMZ/RT→TMZ (MGMT 
methylated) 
Nitrosourea or TMZ 
rechallenge or bevacizumab4, 
RT for RT-naïve patients 
42  
     
 Diffuse midline glioma, H3-K27M 
mutant 
RT or TMZ/RT→TMZ   
     
 Oligodendroglioma, IDH-mutant and 
1p/19q-codeleted 
Wait-and-see or RT→PCV (or 
PCV→RT) 
TMZ or bevacizumab4 Per extrapolation from WHO 
grade III tumors72,73 and 
RTOG 980224 
 Oligodendroglioma, NOS Wait-and-see or RT→PCV (or 
PCV→RT) 
TMZ or bevacizumab4 Per extrapolation from WHO 
grade III tumors72,73 and 
RTOG 980224 
     
 Anaplastic oligodendroglioma, IDH-
mutant and 1p/19q-codeleted 
RT→PCV (or PCV→RT) TMZ or bevacizumab4 72,73 
 Anaplastic oligodendroglioma, NOS RT→PCV (or PCV→RT) TMZ or bevacizumab4 72,73 
 
     
 Oligoastrocytoma, NOS Wait-and-see or RT→PCV (or 
PCV→RT) 
TMZ or bevacizumab4 Per extrapolation from WHO 
grade III tumors72,73 
and RTOG 980224 
 Anaplastic oligoastrocytoma, NOS RT→PCV (or PCV→RT) TMZ or bevacizumab4 72,73 
     
 Other astrocytic tumors    
 Pilocytic astrocytoma 
 Pilomyxoid astrocytoma 
Surgery only Surgery → RT  
 Subependymal giant cell astrocytoma Surgery only Surgery  
 Pleomorphic xanthoastrocytoma Surgery only Surgery  
 Anaplastic pleomorphic RT Surgery → ChT (TMZ)  
43 
 
xanthoastrocytoma 
 
1maximum safe resection is recommended whenever feasible in all patients with newly diagnosed gliomas 
2second surgery should always be considered, but clinical benefit may be limited to patients where a gross total resection can be achieved 
3reexposure to TMZ and less so nitrosourea treatment has little activity in tumors lacking MGMT promoter methylation 
4depending on local availability 
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Table 2 - Chemotherapy protocols in malignant gliomas 
 
Protocol Dose and mode of administration 
TMZ 75 mg/m2 daily p.o. including weekends during RT 
150–200 mg/m2 D1- D5 p.o. fasting in the morning every 
4 weeks for 6 cycles of maintenance treatment 
ACNU (nimustine), BCNU 
(carmustine), CCNU 
(lomustine), fotemustine 
Different regimens, most commonly CCNU p.o. 110 
mg/m2 every 6 weeks 
PCV Procarbazine 60 mg/m2 p.o. D8–D21  
CCNU 110 mg/m2 p.o. D1 
Vincristine 1.4 mg/m2 i. v. (maximum 2 mg) D8 +D29 x 
(6-)8 weeks 
Bevacizumab 10 mg/m2 x 2 weeks 
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Table 3 - Key recommendations* 
 
General C L 
Karnofsky performance score (KPS), neurological function, age, and 
individual risks and benefits should be considered for clinical decision 
making. 
I A 
Screening and prevention have no major role for patients with gliomas. IV - 
Patients with relevant germ line variants or suspected hereditary cancer 
syndromes should receive genetic counselling and based on that might 
be referred for molecular genetic testing. 
IV - 
The diagnostic imaging approach of first choice is magnetic resonance 
imaging (MRI) without and with contrast enhancement. 
IV - 
Peudoprogression should be considered in patients with an increase of 
tumor volume on neuroimaging in the first months after local therapeutic 
interventions including radiotherapy and experimental local treatments. 
II B 
Clinical decision making without obtaining a definitive WHO diagnosis at 
least by biopsy should occur only in very exceptional situations. 
IV - 
Glioma classification should follow the new WHO classification of tumors 
of the central nervous system 2016. 
IV - 
Immunohistochemistry for mutant IDH1-R132H protein and nuclear 
expression of ATRX should be performed routinely in the diagnostic 
IV - 
46 
 
assessment of gliomas. 
IDH mutation status should be assessed by immunohistochemistry for 
IDH1-R132H. If negative, immunohistochemistry should be followed by 
sequencing of IDH1 codon 132 and IDH2 codon 172 in all WHO grade II 
and III astrocytic and oligodendroglial gliomas and in all glioblastomas of 
patients younger than 55 years of age to allow for integrated diagnoses 
according to the WHO classification and to guide treatment decisions. 
IV - 
1p19q co-deletion status should be determined in all IDH-mutant gliomas 
with retained nuclear expression of ATRX. 
II B 
MGMT promoter methylation status should be determined in elderly 
patients with glioblastoma and in IDH-wildtype WHO grade II/III gliomas 
to guide decision for the use of TMZ instead of or in addition to RT. 
I B 
Since extent of resection is a prognostic factor, efforts at obtaining 
complete resections are justified across all glioma entities. 
IV - 
The prevention of new permanent neurological deficits has higher priority 
than extent of resection in the current surgical approach to gliomas. 
IV - 
IDH-mutant WHO grade II/III gliomas   
Standard of care for (1p/19q-non-codeleted) WHO grade II diffuse 
astrocytoma requiring further treatment includes resection as feasible or 
biopsy followed by involved field RT and maintenance PCV (RTOG 
9802).24 
II B 
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Standard of care for 1p/19q-non-codeleted anaplastic astrocytoma 
includes resection as feasible or biopsy followed by involved field RT and 
maintenance TMZ (CATNON).27 
II B 
Patients with 1p/19q-codeleted WHO grade II oligodendroglial tumors 
requiring further treatment should be treated with radiotherapy plus PCV 
chemotherapy. 
III B 
Patients with 1p/19q-codeleted anaplastic oligodendroglial tumors should 
be treated with radiotherapy plus PCV chemotherapy (EORTC 26951, 
RTOG 9402).72,73  
II B 
Temozolomide chemotherapy is standard treatment at progression after 
surgery and radiotherapy for most patients with WHO grade II/III gliomas. 
II B 
Glioblastoma, IDH-wildtype (WHO grade IV)   
Standard of care for glioblastoma, IDH-wildtype (age < 70 years, KPS > 
70) includes resection as feasible or biopsy followed by involved-field 
radiotherapy and concomitant and maintenance (6 cycles) TMZ 
chemotherapy (TMZ/RT→TMZ) (EORTC 26981 NCIC CE.3).42  
I A 
TMZ is particularly active in patients with MGMT promoter methylation 
whereas its activity in patients with MGMT promoter-unmethylated tumors 
is marginal.45 
II B 
Elderly patients not considered candidates for TMZ/RT→TMZ should be 
treated based on MGMT promoter methylation status (NOA-08, Nordic 
Trial, NCIC CE.6/EORTC 6062) with radiotherapy (e.g., 15 x 2.66 Gy) or 
II B 
48 
 
TMZ (5/28).39,40,52 
At recurrence, standards of care are less well defined. Nitrosourea 
regimens, TMZ re-challenge and, with consideration of the country-
specific label, bevacizumab are options of pharmacotherapy, but an 
impact on OS remains unproven. When available, recruitment into 
appropriate clinical trials should be considered. 
II B 
 
*C class of evidence, *level of recommendation79 
 
 
Figure Legends 
 
Figure 1. Graphic illustration of a commonly used diagnostic algorithm for integrated 
classification of diffuse astrocytic and oligodendroglial gliomas according to the WHO 
classification 2016 (Louis et al. 2016). Following histological analysis, diffuse gliomas 
of WHO grade II, III or IV are assessed by immunohistochemistry for IDH1-R132H 
mutation and loss of nuclear expression of ATRX protein. In case of diffuse gliomas 
located in midline structures (thalamus, brain stem and spinal cord), immunostaining 
for histone 3 K27M (H3-K27M) mutation characterizes diffuse midline gliomas, H3-
K27M-mutant. Following immunohistochemistry, molecular analyses for less common 
IDH1 codon 132 mutations (other than R132H) or IDH2 codon 172 mutations (e.g. by 
DNA sequencing) as well as for codeletion of chromosomal arms 1p and 19q (e.g. by 
fluorescent in situ hybridization or microsatellite PCR-based loss of heterozygosity 
analyses) are carried out according to the individual immunhistochemical results. 
*IDH-mutation and loss of nuclear ATRX expression suffice for classification as IDH-
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mutant astrocytic gliomas. Additional molecular testing for 1p/19q codeletion is not 
routinely required but may be performed to further substantiate the diagnosis, e.g. in 
cases with ambigous histology. **In patients older than 55 years of age at diagnosis 
with a histologically typical glioblastoma, without a pre-existing lower grade glioma 
and with non-midline tumor location, immunohistochemical negativity for IDH1-
R132H suffices for classification as glioblastoma, IDH-wildtype. In all other instances 
of diffuse gliomas, lack of IDH1-R132H immunopositivy should be followed by IDH1 
and IDH2 sequencing to detect or exclude other, less common IDH mutations. 
***IDH-wildtype diffuse astrocytic gliomas with loss of nuclear ATRX expression may 
be additionally tested histone 3 mutations. Abbreviations: A II, diffuse astrocytoma 
WHO grade II; AA III, anaplastic astrocytoma WHO grade III; GB IV, glioblastoma 
WHO grade IV; O II, oligodendroglioma WHO grade II; AO III, anaplastic 
oligodendroglioma WHO grade III. The provisional WHO entities of diffuse 
astrocytoma, IDH-wildtype, and anaplastic astrocytoma, IDH-wildtype, are indicated 
in italics. 
 
Figure 2. Clinical Pathway “Glioma”. 
 
Figure 3. Diagnostic and therapeutic approach to gliomas in adulthood. Note that the 
option of supportive care exists across the entities, but is not included for clarity. 
 
